The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
If you picked Recursion Pharmaceuticals for its AI-first pitch and deep pharma ties, the past year has probably felt rough.
Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering ...
In a Nov. 1 blog post, software engineer Nicolas Chagnet argues that Gleam pairs a simple functional syntax with the Erlang ...
In addition to that, given the crosstalk that is known between MAPK pathway and beta-catenin, MEK1/2 can also dampen some of the growth signals driven by APC loss. It is that platform insight that led ...
Google open-sourced Harness2, a recursive agent harnessing framework that lifted GLM-5 11.5 points on WorkBuddy-Bench with frozen weights.
Worker move goods for despatch in a redistribution centre of US online retail giant Amazon in Horn-Bad Meinberg, western Germany, on December 9, 2024. INA FASSBENDER/AFP via Getty Images Cloudflare's ...
Recursive self-improvement is already visible in large language models, but mostly in limited forms. Today's LLMs can revise answers, improve agent skills, write better prompts, generate training data ...